One origin technical dossier, twelve LATAM regulators: the parallel localization matrix

The most expensive Latin American registration pattern I still see is this: twelve countries, twelve distributors, twelve separate sworn translations of the same IFU, and twelve slightly different Spanish words for the same intended use. The manufacturer did not mean to build twelve products. The process did.

I'm Julio Martinez-Clark. Amavita Sciences™ exists to stop that pattern. After years of putting device files in front of Latin American agencies with bioaccess®, we built a localization practice around one idea: most of the technical dossier is shared; only the linguistic and administrative edges are national. If you engineer the shared core once, you can file in parallel without paying to reinvent the device in every capital.

Disconnected local distributors often commission their own translations because it feels faster. Three problems follow.

First, redundant cost. Biocompatibility, sterilization validation, risk analysis under ISO 14971, bench testing and software documentation get re-translated for each market even though the science did not change.

Second, inconsistent clinical terminology. One country pack says one indication phrase; another pack drifts. Reviewers who compare files, or a later audit that traces claims across markets, find discrepancies the manufacturer never intended.

Third, control risk. When each distributor owns "its" translation memory, the manufacturer loses a single source of truth for labeling and IFU language. Updating a warning then becomes twelve projects instead of one change control.

Parallel localization is the opposite design: the manufacturer keeps the master dossier and the termbase; local partners receive country packs that are derived, not reinvented.

For IMDRF-aligned device files, a large share of the technical submission is structurally the same across agencies:

• Biocompatibility evidence (typically ISO 10993 family reports).
• Sterilization validation (for example ISO 11135 or ISO 11137, as applicable).
• Risk management under ISO 14971.
• Bench, electrical safety and software documentation where the device includes those elements.
• Clinical evaluation narrative modules that describe the same device and intended use.

Operator experience across multi-country programs is that the majority of that technical mass — often on the order of most of the scientific annex volume — can stay in a controlled master and be reused. I am deliberately not selling a fake precise percentage. The reusable share depends on device class, software content and how divergent the intended-use claims are. The planning point is directionally the same: rebuild the science once; vary the edges.

What does change by country is still real work:

• Language variant (Brazilian Portuguese vs Latin American Spanish).
• Labeling and IFU mandatory content.
• Administrative and legal annexes (powers of attorney, free-sale certificates, registration-holder instruments).
• Platform and fee mechanics (ANVISA petitions, COFEPRIS DIGIPRIS flows, INVIMA channels, and the rest).
• Whether a given annex may stay in the original language with a local-language summary (Colombia's Circular 1298 pattern is one example we have written about separately).

Brazil: Brazilian Portuguese, ANVISA shape

Brazil is not "Spanish with different spelling." Brazilian Portuguese IFUs, technical labeling and petition language follow ANVISA's rules (including RDC 751/2022 for devices and, where relevant, reliance under IN 290/2024). Sworn translation (tradução juramentada) appears for specific legal and foreign-language instruments. A Spanish master does not file in Brasília.

Spanish-speaking Latin America: one language, several regulator dialects

Spanish is shared. Regulator lexicon is not identical. COFEPRIS, INVIMA, Chile's ISP, Peru's DIGEMID and Argentina's ANMAT do not always use the same preferred terms for device categories, contraindications or clinical endpoints. A single Spanish termbase with country-allowed variants beats twelve freelancers inventing synonyms.

Sworn translation (traductor público) versus certified technical translation is a document-type decision, not a country slogan. Legal instruments and some certificates need sworn treatment. IFUs and manuals usually need certified technical translation with medical review. Mixing those tiers is how files get rejected for form, not for science.

Twelve-country scope we mean in practice

When we say a twelve-country parallel matrix, we mean a manufacturer-ready plan that can reach the major device markets and corridors sponsors actually ask us to stage together — typically some set of Brazil, Mexico, Colombia, Argentina, Chile, Peru, Costa Rica, Panama, El Salvador, Dominican Republic, Uruguay and Guatemala or a comparable twelve-market mix. The exact twelve follows the commercial plan. The architecture does not change: one master, many annexes.

Here is the operating model that keeps ownership with the manufacturer:

1. Freeze a master technical dossier in the source language (and English if that is the working language of the design history). Lock device name, intended use, warnings and numerical claims.
2. Build one controlled termbase for Spanish and one for Brazilian Portuguese before mass localization starts.
3. Produce shared Spanish and Portuguese technical modules once — clinical evaluation, risk summary, IFU core, labeling core.
4. Generate country annex packs: administrative forms, local declarations, fee proofs, platform uploads, and any agency-specific wording overlays.
5. Assign local distributors or registration holders as commercial and regulatory actors without handing them uncontrolled translation ownership. They file; they do not freestyle the IFU.
6. Run change control centrally. A labeling update ships from the master to every open country pack on purpose, not by email chain.

That architecture is what makes true parallel filing possible. If country two waits for country one's translator to finish inventing terms, you do not have parallelism. You have a queue with extra invoices.

Amavita Sciences™ does not publish per-word rates. Per-word economics reward volume. Regulatory localization rewards correct document roles and first-cycle acceptance. We also do not promise that parallel filing removes agency questions. It removes self-inflicted inconsistency and duplicated scientific translation. Agency clocks remain agency clocks.

We run files through a six-step pipeline — Upload, Localization, Medical Review, Regulatory QA, Export Package, Submission Ready — described on our platform page. Regulatory QA is where country annexes are checked against the master so Brazil and Mexico do not silently disagree about the indication sentence.

In a well-run program, scientific localization for Spanish and Brazilian Portuguese starts as soon as the master intended use is frozen — not after the first agency accepts a file. Country administrative packs are prepared on overlapping tracks while apostilles and powers of attorney move through their own lanes. The first file to submit is often the one whose legal annexes cleared first, not the one whose science was "more important." Science was already shared. That calendar design is how you get concurrent submissions without concurrent chaos.

• Do you have a single owner for the master IFU and termbase?
• Is intended use identical across the countries you plan to file, or are you actually registering different claim sets?
• Which annexes are scientific (reuse) versus administrative (localize)?
• Which documents need sworn translation versus certified technical translation?
• Who is the registration holder in each market, and do they receive a controlled pack or an editable free-for-all?
• What is the change-control path when engineering updates a warning next quarter?

If you cannot answer those, twelve parallel filings will multiply confusion faster than they multiply approvals.

Reliance and abbreviated routes (for example ANVISA IN 290/2024 for listed EFRAs, or Mexico's COFEPRIS abbreviated pathway) make the shared-core model more valuable, not less. When an agency agrees to take another regulator's assessment as reference, the remaining differentiator is whether your local-language dossier is consistent and complete. A messy twelve-translator stack wastes the calendar reliance just bought you.

Review Amavita Sciences™ twelve-country regulatory dossier translation and localization framework at amavitasciences.com when you want the master dossier and the country packs designed as one system instead of twelve separate bets.